Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | TP53 | P04637 | 3/20 | 0.63 |
| ▸ | THRB | P10828 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 3/20 | 0.58 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.58 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5242203 | 0.92 | LMNA (0.62) | LMNAALDH1A1MAPTTP53THRB | |
| SCHEMBL5243318 | 0.89 | MAPT (0.72) | LMNAALDH1A1MAPTTP53MEN1 | |
| SCHEMBL5243720 | 0.89 | LMNA (0.55) | LMNAALDH1A1MAPTTP53THRB | |
| SCHEMBL5246662 | 0.89 | PKM (0.67) | LMNAALDH1A1MAPTTP53THRB | |
| SCHEMBL5243803 | 0.89 | ALDH1A1 (0.65) | LMNAALDH1A1TP53USP2MEN1 | |
| SCHEMBL5242874 | 0.86 | MAPT (0.79) | LMNAALDH1A1MAPTTP53 | |
| SCHEMBL5246510 | 0.85 | HSD11B1 (0.54) | LMNAALDH1A1MAPTTP53MEN1 | |
| SCHEMBL5246722 | 0.85 | HSD11B1 (0.65) | LMNAALDH1A1MAPTTP53THRB | |
| SCHEMBL5243056 | 0.84 | PKM (0.81) | LMNAALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL5244947 | 0.83 | HSD11B1 (0.55) | LMNAMAPTTP53KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1866285-A1 | 1-SULFONYL-PIPERDINE-3-CARBOXYLIC ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS | F. Hoffmann-Roche AG (CH) | 2007-12-19 | — | — | EP | claimed |
| WO-2006094633-A1 | 1- SULFONYL-PI PERDINE- 3 -CARBOXYL I C ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | claimed |
| EP-1866285-A1 | 1-SULFONYL-PIPERDINE-3-CARBOXYLIC ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS | F. Hoffmann-Roche AG (CH) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006094633-A1 | 1- SULFONYL-PI PERDINE- 3 -CARBOXYL I C ACID AMIDE DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE FOR THE TREATMENT OF TYPE II DIABETES MELLITUS | F. HOFFMAN-LA ROCHE AG (CH) | 2006-09-14 | — | — | WO | disclosed |
| US-20060199816-A1 | Aryl sulfonyl piperidines | GILLESPIE PAUL | 2006-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199816-A1 | Aryl sulfonyl piperidines | GPR119, SLC5A2, GLS2 | LMNA 3687/4885ALDH1A1 88/4885MAPT 4530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.